Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.85 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.85 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.85 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.85 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.85 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.85 |
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.48 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1396413 | 0.92 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL1396283 | 0.90 | GABRA1 (0.72) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL1590908 | 0.87 | GABRA1 (0.85) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL1396260 | 0.84 | GABRA1 (0.85) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL1590687 | 0.84 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL1591243 | 0.84 | GABRA1 (0.82) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL1591811 | 0.84 | GABRA1 (0.78) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL1396226 | 0.83 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL1396306 | 0.82 | GABRA1 (0.79) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL1396324 | 0.82 | GABRA1 (0.83) | GABRA1GABRG2GABRB3GABRA3GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372348-A1 | LIPID FORMULATIONS OF TRIAZOLOQUINAZOLINONE COMPOUNDS | GABATHER AB (SE) | 2023-11-23 | — | — | US | claimed |
| CN-116806147-A | Lipid formulations of triazoloquinazolinone compounds | 加巴瑟公司 | 2023-09-26 | — | — | CN | claimed |
| EP-4225275-A1 | LIPID FORMULATIONS OF TRIAZOLOQUINAZOLINONE COMPOUNDS | Gabather AB (SE) | 2023-08-16 | — | — | EP | claimed |
| EP-3752507-B1 | TRIAZOLOQUINAZOLINONE SYNTHESIS | GABATHER AB (SE) | 2022-11-16 | — | — | EP | claimed |
| WO-2022074457-A1 | LIPID FORMULATIONS OF TRIAZOLOQUINAZOLINONE COMPOUNDS | GABATHER AB (SE) | 2022-04-14 | — | — | WO | claimed |
| US-20210087193-A1 | TRIAZOLOQUINAZOLINONE SYNTHESIS | GABATHER AB (SE) | 2021-03-25 | — | — | US | claimed |
| EP-2288612-B1 | GABAA RECEPTOR MODULATORS | GABATHER AB (SE) | 2015-07-29 | — | — | EP | claimed |
| US-8809355-B2 | GABAA receptor modulators | INNOVATIONSPATENT SVERIGE AB (SE) | 2014-08-19 | — | — | US | claimed |
| US-20230372348-A1 | LIPID FORMULATIONS OF TRIAZOLOQUINAZOLINONE COMPOUNDS | GABATHER AB (SE) | 2023-11-23 | — | — | US | disclosed |
| US-20230372348-A1 | LIPID FORMULATIONS OF TRIAZOLOQUINAZOLINONE COMPOUNDS | GABATHER AB (SE) | 2023-11-23 | — | — | US | disclosed |
| US-20230372348-A1 | LIPID FORMULATIONS OF TRIAZOLOQUINAZOLINONE COMPOUNDS | GABATHER AB (SE) | 2023-11-23 | — | — | US | disclosed |
| CN-116806147-A | Lipid formulations of triazoloquinazolinone compounds | 加巴瑟公司 | 2023-09-26 | — | — | CN | disclosed |
| EP-4225275-A1 | LIPID FORMULATIONS OF TRIAZOLOQUINAZOLINONE COMPOUNDS | Gabather AB (SE) | 2023-08-16 | — | — | EP | disclosed |
| EP-3752507-B1 | TRIAZOLOQUINAZOLINONE SYNTHESIS | GABATHER AB (SE) | 2022-11-16 | — | — | EP | disclosed |
| US-20210087193-A1 | TRIAZOLOQUINAZOLINONE SYNTHESIS | GABATHER AB (SE) | 2021-03-25 | — | — | US | disclosed |
| EP-3752507-A1 | TRIAZOLOQUINAZOLINONE SYNTHESIS | Gabather AB (SE) | 2020-12-23 | — | — | EP | disclosed |
| WO-2019123011-A1 | TRIAZOLOQUINAZOLINONE SYNTHESIS | GABATHER AB (SE) | 2019-06-27 | — | — | WO | disclosed |
| EP-2288612-B1 | GABAA RECEPTOR MODULATORS | GABATHER AB (SE) | 2015-07-29 | — | — | EP | disclosed |
| US-8809355-B2 | GABAA receptor modulators | INNOVATIONSPATENT SVERIGE AB (SE) | 2014-08-19 | — | — | US | disclosed |
| US-20110092525-A1 | GABAA RECEPTOR MODULATORS | GABATHER AB (SE) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372348-A1 | LIPID FORMULATIONS OF TRIAZOLOQUINAZOLINONE COMPOUNDS | SOAT1, DGAT1, CPT1A | GABRA1 3287/4885GABRG2 3981/4885GABRB3 4161/4885 |
| US-20210087193-A1 | TRIAZOLOQUINAZOLINONE SYNTHESIS | CYP3A5, CYP2C19, CYP3A7 | GABRA1 2776/4885GABRG2 3184/4885GABRB3 2939/4885 |
| US-20110092525-A1 | GABAA RECEPTOR MODULATORS | GABRA5, GABRA1, GABRA2 | GABRA1 2/4885GABRG2 13/4885GABRB3 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.